Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 26;40(1):60-66.
doi: 10.5937/jomb0-24689.

Clinical relevance of lipid panel and aminotransferases in the context of hepatic steatosis and fibrosis as measured by transient elastography (FibroScan®)

Luis Alberto Chi-Cervera  1 , Gordon Iaarah Montalvo  1 , María Eugenia Icaza-Chávez  1 , Julio Torres-Romero  2 , Víctor Arana-Argáez  3 , Mario Ramírez-Camacho  4 , Julio Lara-Riegos  2
Affiliations

Clinical relevance of lipid panel and aminotransferases in the context of hepatic steatosis and fibrosis as measured by transient elastography (FibroScan®)

Luis Alberto Chi-Cervera et al. J Med Biochem. .

Abstract
in English, Serbian

Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease and is associated with various co-morbidities. Transient elastography (FibroScan®) is a non-invasive method to detect NAFLD using the controlled attenuation parameter (CAP). We aimed to evaluate the association of the lipid panel and aminotransferases concentrations with the presence or absence of steatosis and fibrosis.

Methods: One hundred and five patients with NAFLD were included. Hepatic steatosis was quantified by CAP (dB/m) and liver stiffness by Kilopascals (kPa), these values were then analyzed against patient lipid panel and serum concentrations of the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT). A correlation and multiple regression were used. Mann-Whitney U test was used as non-parametric analysis.

Results: We observed an association between hepatic steatosis and total cholesterol (B = 0.021, p = 0.038, Exp (B) = 1.021, I.C = 1.001-1.041) as well as serum triglycerides (B = 0.017, p = 0.006, Exp (B) = 1.018 and I.C = 1.005-1.030). Similarly, we found an association between significant hepatic fibrosis and lower concentrations of total cholesterol (B = -0.019, p = 0.005, Exp (B) = 0.982 I.C = 0.969-0.995) and elevated AST (B = 0.042, p = 3.25 × 10-4, Exp (B) = 1.043 I.C = 1.019-1.068) independent of age, gender and BMI.

Conclusions: Our results suggest that, total cholesterol and triglyceride concentrations positively correlate with hepatic steatosis while significant hepatic fibrosis is associated with lower total cholesterol and higher AST concentrations.

Uvod: Oboljenje nealkoholna masna jetra (NAFLD) je jedan od najčešćih uzročnika hroničnog oboljenja koje je praćeno nizom različitih komorbiditeta. Kratkotrajna elastografija (FibroScan®) je neinvazivni metod za otkrivanje NAFLD primenom kontrolisanog prigušenog parametra (CAP). Namera je bila da se proceni veza između koncentracija lipidnog panela i aminotransferaza sa prisustvom ili odsustvom steatoze i fibroze.

Metode: U ispitivanje je uključeno sto pedeset pacijenata sa NAFLD. Hepatična steatoza je merena pomoću CAP (dB/m) a krutost jetre pomoću kilopaskala (kPA), da bi zatim ove vrednosti bile analizirane prema vrednostima lipidnog panela i serumskih koncentracija jetrenih enzima aspartat aminotransferaze (AST) i alanin aminotransferaze (ALT). Za procenu su korišćena korelacija i multipla regresija. Mann-Whitney U test je korišćen kao ne-parametarska analiza.

Rezultati: Posmatrana je veza između hepatične steatoze i ukupnog holesterola (B = 0,021, p = 0,038, Exp (B) = 1,021, I.C = 1,001-1, 041) kao i serumskih triglicerida (B = 0,017, p = 0,006, Exp (B) = 1,018 i I.C = 1,005-1,030). Nađena je slična veza između značajne hepatične fibroze i nižih koncentracija ukupnog holesterola (B = -0,019, p = 0,005, Exp(B) = 0,982, I.C = 0,969-0,995) i povišene AST (B = 0,042, P = 3.25 × 10-4, Exp (B) = 1,043, I.C = 1,019-1,068) nezavisno od starosti, pola i BMI.

Zaključak: Dobijeni rezultati pokazuju da su koncentracije ukupnog holesterola i triglicerida u pozitivnoj korelaciji sa hepatičnom steatozom dok je značajna hepatična fibroza u vezi sa sniženim ukupnim holesterolom i višim koncentracijama AST.

Keywords: fibrosis; lipids; liver disease; liver enzymes; steatosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors stated that they have no conflicts of interest regarding the publication of this article.

Figures

Figure 1
Figure 1. Boxplot graphic of median with interquartile range of (A-D) lipid panel and (E) aspartate aminotransferase (AST) and (F) alanine aminotransferase (ALT), according to hepatic steatosis and significant hepatic fibrosis
The vertical line represents the division between the hepatic steatosis and advanced fibrosis analyses. P values were determined by the Mann-Whitney U test.
See this image and copyright information in PMC

References

    1. Younossi Z, Anstee Q M, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and Nash: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11. doi: 10.1038/nrgastro.2017.109. - DOI - PubMed
    1. Sanyal A J, Chalasani N, Kowdley K V, Mccullough A, Diehl A M, Bass N M, Neuschwander-Tetri B A, Lavine J E, Tonascia J, Unalp A, van Natta M, Clark J, Brunt E M, Kleiner D E. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675. doi: 10.1056/nejmoa0907929. - DOI - PMC - PubMed
    1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221. doi: 10.1056/nejmra011775. - DOI - PubMed
    1. Fabbrini E, Magkos F, Mohammed B S, Pietka T, Abumrad N A, Patterson B W, et al Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106(36):15430. - PMC - PubMed
    1. Nassir F, Rector R S, Hammoud G M, Ibdah J A. Pathogenesis and prevention of hepatic steatosis. Gastroenterology & Hepatology. 2015;11(3):167. - PMC - PubMed

LinkOut - more resources